Allos Therapeutics Announces CEO Succession Plans
Mr. Hart joined Allos in 1999 and was promoted to President and CEO in December 2001 and to the Board of Directors in April 2002. Prior to his promotion he was Chief Financial Officer and Senior Vice President, Operations. During Mr. Hart's tenure, the Company received an approvable letter from the FDA for its lead compound EFAPROXYN for the treatment of patients with brain metastases originating from breast cancer, added PDX and RH1 to its product portfolio and gained significant financial strength through four successful stock offerings that collectively generated $170 million, including the Company's IPO in March 2000.
Most read news
Other news from the department people
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.